Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to -$15.3 million.

  • Precision Biosciences' Free Cash Flow fell 15659.55% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 5200.99%. This contributed to the annual value of -$58.7 million for FY2024, which is 3180.63% up from last year.
  • As of Q3 2025, Precision Biosciences' Free Cash Flow stood at -$15.3 million, which was down 15659.55% from -$20.3 million recorded in Q2 2025.
  • Precision Biosciences' 5-year Free Cash Flow high stood at $66.9 million for Q1 2021, and its period low was -$33.0 million during Q2 2021.
  • Its 5-year average for Free Cash Flow is -$13.9 million, with a median of -$20.3 million in 2025.
  • Per our database at Business Quant, Precision Biosciences' Free Cash Flow skyrocketed by 34783.25% in 2021 and then tumbled by 18356.71% in 2023.
  • Precision Biosciences' Free Cash Flow (Quarter) stood at -$25.2 million in 2021, then increased by 10.76% to -$22.5 million in 2022, then soared by 62.64% to -$8.4 million in 2023, then plummeted by 123.65% to -$18.8 million in 2024, then increased by 18.69% to -$15.3 million in 2025.
  • Its Free Cash Flow was -$15.3 million in Q3 2025, compared to -$20.3 million in Q2 2025 and -$19.1 million in Q1 2025.